Your browser is no longer supported. Please, upgrade your browser.
GLPG Galapagos NV daily Stock Chart
Galapagos NV
Index- P/E- EPS (ttm)-1.69 Insider Own- Shs Outstand65.34M Perf Week-9.62%
Market Cap8.61B Forward P/E- EPS next Y-5.45 Insider Trans- Shs Float41.88M Perf Month-5.64%
Income- PEG- EPS next Q-1.64 Inst Own11.71% Short Float3.36% Perf Quarter-36.65%
Sales- P/S- EPS this Y-291.70% Inst Trans- Short Ratio9.09 Perf Half Y-37.09%
Book/sh25.49 P/B5.17 EPS next Y-3.00% ROA- Target Price164.48 Perf Year-16.33%
Cash/sh- P/C- EPS next 5Y0.71% ROE- 52W Range112.00 - 274.03 Perf YTD-36.28%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-51.91% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low17.67% ATR4.42
Employees1280 Current Ratio- Sales Q/Q74.10% Oper. Margin- RSI (14)41.16 Volatility2.09% 2.17%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.43 Prev Close130.40
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume154.59K Price131.79
Recom3.00 SMA20-6.08% SMA50-8.43% SMA200-31.49% Volume66,574 Change1.07%
Aug-25-20Downgrade Jefferies Buy → Hold
Aug-24-20Downgrade H.C. Wainwright Buy → Neutral $270 → $123
Aug-19-20Upgrade Citigroup Neutral → Buy
Aug-19-20Downgrade Barclays Overweight → Equal Weight
Jul-10-20Downgrade Stifel Buy → Hold $298 → $193
Mar-30-20Upgrade Jefferies Hold → Buy $232
Mar-18-20Upgrade RBC Capital Mkts Underperform → Sector Perform $175 → $157
Feb-25-20Downgrade Cantor Fitzgerald Overweight → Neutral
Feb-24-20Downgrade BofA/Merrill Neutral → Underperform
Feb-20-20Downgrade RBC Capital Mkts Sector Perform → Underperform $175
Jan-06-20Downgrade JP Morgan Overweight → Neutral
Dec-18-19Downgrade Citigroup Buy → Neutral
Dec-17-19Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-13-19Downgrade Credit Suisse Outperform → Neutral $174 → $169
Dec-02-19Initiated BofA/Merrill Neutral
Sep-09-19Resumed Morgan Stanley Overweight
Jul-31-19Upgrade UBS Neutral → Buy
Jul-29-19Downgrade Jefferies Buy → Hold
Jul-15-19Reiterated H.C. Wainwright Buy $150 → $205
Jul-10-19Resumed Credit Suisse Outperform
Oct-16-20 07:15AM  
Oct-15-20 04:19PM  
Oct-13-20 03:10PM  
Oct-12-20 09:15AM  
Oct-01-20 01:54PM  
Sep-29-20 04:01PM  
Sep-28-20 03:01PM  
Sep-27-20 05:52AM  
Sep-25-20 01:00PM  
Sep-18-20 04:01PM  
Sep-14-20 10:28AM  
Sep-13-20 06:17PM  
Sep-11-20 08:05AM  
Sep-10-20 10:30PM  
Sep-01-20 11:15PM  
Aug-28-20 07:45AM  
Aug-26-20 01:30AM  
Aug-25-20 10:45PM  
Aug-21-20 01:54AM  
Aug-20-20 05:28PM  
Aug-19-20 08:01PM  
Aug-18-20 07:25PM  
Aug-12-20 04:01PM  
Aug-06-20 04:01PM  
Jul-24-20 08:14AM  
Jul-07-20 06:48PM  
Jul-02-20 10:38AM  
Jun-26-20 12:31PM  
Jun-07-20 11:15AM  
Jun-05-20 04:01PM  
Jun-04-20 10:03AM  
May-21-20 11:20AM  
May-20-20 04:03PM  
May-11-20 06:52AM  
May-09-20 10:00PM  
Apr-25-20 11:56AM  
Apr-24-20 11:41AM  
Apr-22-20 09:07AM  
Apr-16-20 02:12AM  
Mar-18-20 02:29PM  
Mar-17-20 02:38PM  
Mar-06-20 06:10AM  
Feb-05-20 09:21AM  
Jan-16-20 10:34AM  
Jan-15-20 08:22AM  
Jan-06-20 10:21AM  
Jan-03-20 05:43PM  
Dec-26-19 10:26AM  
Dec-20-19 08:27AM  
Dec-13-19 04:06PM  
Dec-03-19 03:42PM  
Dec-02-19 02:57PM  
Nov-13-19 07:34AM  
Nov-09-19 04:30PM  
Oct-31-19 04:01PM  
Oct-25-19 10:36AM  
Oct-23-19 10:06AM  
Oct-18-19 11:22AM  
Oct-16-19 04:00AM  
Oct-11-19 09:19AM  
Oct-10-19 06:00PM  
Oct-09-19 11:10AM  
Sep-26-19 12:38PM  
Sep-03-19 05:46PM  
Aug-29-19 09:00AM  
Aug-28-19 10:34AM  
Aug-26-19 08:28AM  
Aug-23-19 04:01PM  
Aug-16-19 09:19AM  
Aug-15-19 04:01PM  
Aug-05-19 01:08PM  
Jul-31-19 09:55AM  
Jul-29-19 04:43PM  
Jul-26-19 06:23PM  
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, Sjogren's syndrome, ankylosing spondylitis, psoriatic arthritis, cutaneous lupus erythematosus, lupus membranous nephropathy, and uveitis. The company's clinical stage programs also comprise GLPG1690, an autotaxin inhibitor that is in ISABELA I and II trials for idiopathic pulmonary fibrosis (IPF), and NOVESA Phase II proof-of-concept trial for systemic sclerosis; and GLPG1205, a GPR84 inhibitor, which is in the PINTA Phase II proof of concept trial for treating IPF. In addition, it engages in the development of GLPG1972, which is in the ROCCELLA Phase 2b trial for treating osteoarthritis; and Toledo molecules, including GLPG3312, GLPG3970, and GLPG4399 for inflammation. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.A r.l.; Novartis Pharma AG; Les Laboratoires Servier and Institut de Recherches Servier; and Ryvu Therapeutics S.A. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.